Malignant Pleural Mesothelioma: Timeline and Analysis of 70 Cases

ByHolly Zink
Malignant Pleural Mesothelioma: Timeline and Analysis of 70 Cases

Malignant pleural mesothelioma is a severe cancer linked to asbestos exposure. It often appears decades after exposure. The disease’s early symptoms are unclear, making it hard to diagnose early.

Despite being rare, this cancer is a major health concern. It has a poor prognosis and few treatment options. A new article details the study of 70 cases at Getafe University Hospital from 2008 to 2021.

Study Overview

The study aimed to detail key aspects of malignant pleural mesothelioma. It covered clinical, histological, radiological, and treatment features. The hospital’s Ethics and Research Committee approved it. The sample involved 70 patients, mainly elderly males with an average age of 71.

Asbestos exposure was found in 61% of cases. Common symptoms were shortness of breath (59%), chest pain (53%), cough (37%), and weight loss (23%).

Primary diagnostic methods included thoracoscopy (59%), image-guided pleural biopsy (21%), thoracotomy (17%), and thoracentesis (4%). Staging showed 50% were in Stage I, 9% in Stage II, 16% in Stage III, and 25% in Stage IV.

Histological analysis revealed 73% had the epithelioid subtype, 14% mixed, and 13% sarcomatoid. Treatments included chemotherapy with carboplatin and pemetrexed (73%), palliative care (16%), and surgery with pleurectomy-decortication (11%). Pleurodesis was done in 30% of patients.

Survival Rates and Prognostic Factors

The study found the group’s median survival was 10 months. Different treatments led to varied outcomes. Surgery resulted in 17 months. Chemotherapy, 10 months. Palliative care, 3 months. Patients with the epithelioid subtype fared better than those with sarcomatoid or mixed subtypes.

Multimodal therapy combines surgery, chemotherapy, and radiation. This improves outcomes. For malignant pleural mesothelioma, it often involves EPD and HITHOC. EPD removes the diseased pleura and other tissues. HITHOC is then applied to the chest to kill remaining cancer cells.

Key Findings

The study found a high rate of malignant pleural mesothelioma in Getafe, Spain. This is due to past asbestos exposure in local industries. Common symptoms were breathing difficulty and chest pain. However, these were not specific to the disease.

Diagnosing the illness was best done through thoracoscopy and CT-guided biopsy. The epithelioid type had a better outlook, especially if fully removed. Unfortunately, advanced stages and the sarcomatoid type led to worse outcomes.

However, the study had limitations. It only focused on one center. It also used retrospective data, which could introduce biases. Clinical recommendations also changed over time, potentially affecting the study’s findings. This restricts how widely the results can be applied.

Malignant Pleural Mesothelioma

The study shows how asbestos exposure raises pleural mesothelioma rates. It stresses early detection and thorough treatment. Multimodal therapy, including surgery, chemo, and radiation, boosts survival odds, especially for early-stage patients. More research and joint registries are crucial for managing the disease.

Understanding the disease’s progression and treatment options helps patients and healthcare providers. It allows for informed decisions, better outcomes, and improved quality of life for those with the disease.

Source:

Garcia-Prieto, Fernando, Sara Calero Pardo, María Teresa Río Ramírez, and Araceli Abad Fernández. “Malignant Pleural Mesothelioma: Analysis of 70 Cases in the Last Decade.” Open Respiratory Archives 6, no. 2 (April 1, 2024): 100326. https://doi.org/10.1016/j.opresp.2024.100326.

Similar Posts

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    ByAlex Strauss

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Mesothelioma Victims’ Victory in Pennsylvania

    ByAlex Strauss

    Workers and their families have won a victory in Pennsylvania after the state Supreme Court ruled that they could sue former employers over late-manifesting industrial diseases like mesothelioma. The decision focused on a provision in Pennsylvania’s Workers’ Compensation Act that says workers cannot sue an employer if their occupational disease occurred more than 300 weeks after their on-the-job exposure. While many occupational injuries and diseases occur within weeks or months of exposure to a toxin, asbestos diseases like mesothelioma are a notable exception. Believed to be caused by chronic irritation from inhaled or ingested asbestos fibers, mesothelioma does not usually begin to cause symptoms until at least a decade after exposure. Expressing the opinion of the majority, Supreme Court Justice…

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    ByAlex Strauss

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • |

    Mesothelioma Still Carries Heavy Mortality Burden in U.S.

    ByAlex Strauss

    Asbestos exposure cost Americans more than 427,000 years of potential life in the first decade of the new millennium. That figure comes from a study on mesothelioma and asbestosis – the two most deadly asbestos-related diseases – conducted by the CDC’s National Institute for Occupational Safety and Health (NIOSH). Using National Center for Health Statistics mortality data, NIOSH researchers evaluated premature deaths and “loss of potentially productive years of life” attributable to either asbestosis or mesothelioma between 1999 and 2010. The data included only people 25 years or older with an underlying cause of death listed on their death certificate of either asbestosis or malignant mesothelioma. When the figures were calculated using the normal life expectancy for each asbestosis victim…